Study_Mentioned
stringlengths 3
205
⌀ | Product_Mentioned
stringlengths 3
429
⌀ | Company_Mentioned
stringlengths 3
288
| Indication_Mentioned
stringlengths 2
111
| Non_Social
int64 1
1
| Tag
stringlengths 2
1.13k
⌀ | Adjusted_Date
stringlengths 11
16
| Conversation_Id
float64 422,000,000B
1,680,000,000B
| Clean_Tweet
stringlengths 1
298
⌀ | Profile_Bio
stringlengths 1
185
⌀ | Class
stringclasses 6
values | User_Type
stringclasses 17
values |
|---|---|---|---|---|---|---|---|---|---|---|---|
OPAL | osimertinib | astrazeneca | thoracic | 1 | ['lung', 'osimertinib'] | 6/6/2022 17:22 | 1,530,000,000,000,000,000 | a phase ii study of osimertinib in combination with platinum plus pemetrexed in patients with egfr-mutated, advanced non small cell lung cancer: the opal study #asco22 orr 90.9% | Medicina Interna - Oncología Clínica - Profesor Titular @UPBColombia - Clínica Astorga. #Medellín / #Colombia mlujanonco@gmail.com #OncTwitter #Metaanalysis | Individual | HCP |
Not Tagged | osimertinib | astrazeneca | thoracic | 1 | ['lung', 'osimertinib'] | 6/6/2022 19:12 | 1,530,000,000,000,000,000 | co-occurring gene alterations associated with efficacy of osimertinib in egfr-mutated lung cancer: based on a large-scale genomic screening project (lc-scrum-asia). #asco22 | Medicina Interna - Oncología Clínica - Profesor Titular @UPBColombia - Clínica Astorga. #Medellín / #Colombia mlujanonco@gmail.com #OncTwitter #Metaanalysis | Individual | HCP |
Not Tagged | Not Tagged | Astrazeneca | Not Tagged | 1 | ['evolution', 'astrazeneca', 'abbott'] | 6/6/2022 21:40 | 1,530,000,000,000,000,000 | #asco : her2 diagnostics need a revolution as #astrazeneca [ ] in their tests runs, the new #assay showed 67 of tumors that were identified ada : #abbott's freestyle libre 3 scores highest accuracy for a 14-day cgm in | Journaliste Français indépendant installé en Suisse, Observateur spécialisé en analyse de reportages et de témoignages internationaux diffusé sur le web | Company / Organization | Blogger / Random / Other |
not tagged | durvalumab | astrazeneca | thoracic | 1 | ['durva', 'durvalumab'] | 6/7/2022 13:40 | 1,530,000,000,000,000,000 | 2022 updates:
after providing significant results in 1st line advanced #biliarytractcancer & positive pros, #durvalumab showed consistent results across regional subgroups as well as no effect on its efficacy by the #hepatitis status. learn more: | #DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry | Company / Organization | Consulting / Analytics |
topaz-1 | durvalumab | astrazeneca | gi | 1 | ['pivotal', 'topaz-1', 'astrazeneca'] | 6/7/2022 13:36 | 1,530,000,000,000,000,000 | 2022 updates: presented the results for patient-reported outcomes and pre-planned secondary objectives from the pivotal topaz-1 trial at the #asco 2022 annual meeting. learn more: #asco #asco22 #asco2022 #oncology #oncologist #cancer | #DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry | Company / Organization | Consulting / Analytics |
ASTRRA | tamoxifen | Astrazeneca | other | 1 | ['ovarian'] | 6/7/2022 13:29 | 1,530,000,000,000,000,000 | #asco22 asstra trial looking at adding 2 yrs ovarian suppression (os) to tamoxifen for women that remained premeno after chemo. via dr. ps: 2-3 yrs a reasonable option, esp for women with diff tolerating it or at risk for cardiovasc. | Translational Medical Oncologist (Biomarkers, Toxicities, Health Outcomes, Clinico-Genomic Big Data) @OncoAlert. Motto: "Let's make a difference". Views mine. | Individual | HCP |
ASTRRA | tamoxifen | Astrazeneca | other | 1 | ['ovarian'] | 6/7/2022 12:28 | 1,530,000,000,000,000,000 | #asco22 #mlmasco - dfs improves by 5.2% at 96 month follow-up when 2-yr ovarian ablation added to tamoxifen in women who remained or restored premenopausal status after adj ct in ebc (korean astrra trial). no os difference. | "What we cannot speak about we must pass over in silence" (L. Wittgenstein) | Individual | Blogger / Random / Other |
ASTRRA | tamoxifen | Astrazeneca | other | 1 | ['ovarian', 'bcsm'] | 6/7/2022 12:03 | 1,530,000,000,000,000,000 | asstra trial looking at adding 2 yrs ovarian suppression (os) to tamoxifen for women that remained premeno after chemo f/u over 100 months dfs benefit w/ os: hr 0.67, 80 to 85% dfs majority of events distant #asco22 #bcsm | Med Onc, Director of Breast & GYN Research Program @ Sarah Cannon Research Institute #bcsm #gyncsm #WomenInMedicine USAF Wife, Mom to 2 girls, tweets are mine. | Individual | HCP |
ASTRRA | tamoxifen | Astrazeneca | other | 1 | ['breast'] | 6/7/2022 12:01 | 1,530,000,000,000,000,000 | oral abstract session at #asco22 on early #breastcancer: super presentation of #astrra trial by my friend hee jeong kim from showing significant 8-y dfs benefit with the addition of 2-y ofs to 5-y #tamoxifen as adjuvant #et in premenopausal patients | Associate Professor at @UniGenova & Medical Oncologist at @SanMartino_Ge. Prior @myESMO fellow. #BreastCancer #Fertility. Big fan of @sampdoria & @giroditalia. | Individual | HCP |
not tagged | durvalumab | astrazeneca | gu | 1 | ['renal,(-adrenal)', 'durva', 'durvalumab'] | 6/7/2022 11:01 | 1,530,000,000,000,000,000 | asco 2022: met and ctla-4 inhibition fail to add benefit to durvalumab therapy in advanced clear cell renal cancer #oncology | Official Twitter account of @PracticeUpdate Oncology. Includes commentaries, journal scans, conference coverage, news items & more. Part of Elsevier. | Bot / Aggregator | Media / News |
not tagged | durvalumab | astrazeneca | gu | 1 | ['renal,(-adrenal)', 'durva', 'durvalumab'] | 6/7/2022 10:01 | 1,530,000,000,000,000,000 | asco 2022: met and ctla-4 inhibition fail to add benefit to durvalumab therapy in clear cell renal cancer #oncology | Official Twitter account of @PracticeUpdate Oncology. Includes commentaries, journal scans, conference coverage, news items & more. Part of Elsevier. | Bot / Aggregator | Media / News |
pacific | durvalumab | astrazeneca | thoracic | 1 | ['pacific'] | 6/7/2022 9:42 | 1,530,000,000,000,000,000 | pacific trial sub-group analysis #asco22 | Vivek Subbiah, MD, (@VivekSubbiah) #PrecisionMedicine Expert and Medical Oncologist, takes over our Twitter today to discuss #ASCO22. | Company / Organization | Media / News |
pacific | durvalumab | astrazeneca | thoracic | 1 | ['pacific'] | 6/7/2022 9:30 | 1,530,000,000,000,000,000 | if you support #cancerdisparities research, you support disaggregation of #pacificislander data since 1997, nhpi is a federal standard us racial category, not #aapi nhpi has been hidden for decades by clinical researchers - time for change | PhD @HopkinsMedicine / MD @MayoClinic / PGY2 Resident @StanfordRadOnc / Cancer #PhysicianScientist / #NativeHawaiian / #IndigenousHealth / @KSNews ‘08 / MyViews | Individual | HCP |
inspire | durvalumab | astrazeneca | gu | 1 | ['inspire'] | 6/7/2022 9:14 | 1,530,000,000,000,000,000 | the inspire phase 2 trial #asco22 | Vivek Subbiah, MD, (@VivekSubbiah) #PrecisionMedicine Expert and Medical Oncologist, takes over our Twitter today to discuss #ASCO22. | Company / Organization | Media / News |
not tagged | not tagged | astrazeneca | other | 1 | ['breast', 'astrazeneca'] | 6/7/2022 9:05 | 1,530,000,000,000,000,000 | breast cancer research is experiencing a transformation as breakthrough advances are being made across multiple treatment settings, tumour types and stages of the disease. learn how we re working to redefine the future of breast cancer research. #asco22 | We're driven by innovative science to deliver life-changing medicines to millions of people worldwide. Community Guidelines: https://t.co/Hj5OdRQOYy | Company / Organization | Pharma / Biotech |
inspire | durvalumab | astrazeneca | gu,other | 1 | ['biomarker', 'inspire'] | 6/7/2022 8:51 | 1,530,000,000,000,000,000 | #asco22 developmental therapeutics/io sci symposium: biomarkers of io vigex gene expression profile (hot/intermed cold/cold, incl pdl1) + ctdna is assoc with response to io across tumour types, validated in the ph ii inspire trial | Thoracic Oncologist focused on immunotherapy for lung cancer & immune toxicity. Beaumont RCSI Cancer Centre Dublin; Adjunct Asst Prof Johns Hopkins University | Individual | HCP |
himalaya | tremelimumab,durvalumab | astrazeneca | other,gi | 1 | ['himalaya', 'bcsm', 'gi '] | 6/7/2022 8:28 | 1,530,000,000,000,000,000 | #asco22 keep refreshing your feeds. himalaya trial now published online 2022 progress for pts with gi malignancies. stride regimen
this idea of just 1 dose of ctla4 is very intriguing! #hpbcsm likely soc | Oncologist | Researcher | ColorectalCancer #CRCSM???????@MayoClinic @PittTweet Alum; ??#ctDNA #LiquidBiopsies??#PrecisionOncology ViewsMy Own. COI @ASCO #ASCO22 | Individual | HCP |
not tagged | not tagged | astrazeneca | not tagged | 1 | ['astrazeneca', 'astrazenecaus'] | 6/7/2022 8:02 | 1,530,000,000,000,000,000 | camille hertzka, head of us oncology medical affairs, shared her perspective on how astrazeneca is leading the effort to advance #healthequity across the #cancer care continuum. #asco22 read more: | The official Twitter feed for AstraZeneca US. For more info visit http://t.co/5VlUaVGyiC. | Company / Organization | Pharma / Biotech |
not tagged | not tagged | astrazeneca | not tagged | 1 | ['astrazeneca'] | 6/7/2022 7:00 | 1,530,000,000,000,000,000 | . partners with nhs for large-scale cancer study
(free w/ registration) #oncology | Med-tech's trusted news source. Lynn Yoffee, Holland Johnson, Mark McCarty, Annette Boyle, Catherine Longworth, Andrea Applegate | Company / Organization | Media / News |
not tagged | durvalumab | astrazeneca | thoracic | 1 | ['durva'] | 6/7/2022 6:12 | 1,530,000,000,000,000,000 | first data of checkrad-cd8 expansion cohorts. #asco22. no increase of pcr rate by addition of treme to cis/doce/durva. enjoy working on the translational research program with you guys! | Radiation Oncology, University Hospital Erlangen | Individual | HCP |
not tagged | not tagged | astrazeneca | not tagged | 1 | ['$azn', 'astrazeneca'] | 6/7/2022 6:05 | 1,530,000,000,000,000,000 | $azn astrazeneca. the data, unveiled at the american society of clinical oncology (asco) meeting in chicago, could open a large, new multibillion-dollar patient population for the drug that won u.s. approval in late 2019 | This week I will mostly be pointing out political deflection by the Conservative party. | Individual | Blogger / Random / Other |
not tagged | not tagged | astrazeneca | not tagged | 1 | ['evolution', 'astrazeneca', 'abbott'] | 6/7/2022 5:58 | 1,530,000,000,000,000,000 | #asco : her2 diagnostics need a revolution as #astrazeneca [ ] in their tests runs, the new #assay showed 67 of tumors that were identified as ada : #abbott #plans new wearable sensor for catching diabetic ketoacidosis. | Journaliste Français indépendant installé en Suisse, Observateur spécialisé en analyse de reportages et de témoignages internationaux diffusé sur le web | Company / Organization | Blogger / Random / Other |
not tagged | not tagged | astrazeneca | not tagged | 1 | ['evolution', 'astrazeneca', 'roche,(-broche),(-rocheter)'] | 6/7/2022 0:59 | 1,530,000,000,000,000,000 | #asco : her2 diagnostics need a revolution as #astrazeneca [ ] investigators used an investigational ihc test developed by #roche, darker skin tonesand that may have led to covid treatment delays, study finds. | Journaliste Français indépendant installé en Suisse, Observateur spécialisé en analyse de reportages et de témoignages internationaux diffusé sur le web | Company / Organization | Blogger / Random / Other |
not tagged | not tagged | astrazeneca,adicet bio,roche,janssen,gilead sciences | not tagged | 1 | ['$jnj', '$azn', '$acet', 'gilead', '$gild', '$rhhby'] | 6/6/2022 11:10 | 1,530,000,000,000,000,000 | #asco22: gilead's tough weekend, bispecific progress and 'gamma delta' cell therapy with $gild $rhhby $jnj $acet $azn | Biotech Journalist; Senior Editor, BioPharma Dive | Individual | Media / News |
Not Tagged | medi-5752,cadonilimab | astrazeneca,akesobio | gu,thoracic | 1 | ['kidney cancer', 'ak-104', 'nsclc', 'medi5752 ', 'sclc'] | 6/5/2022 10:53 | 1,530,000,000,000,000,000 | 2 in 1! keep an eye on pd-1/ctla-4 bispecific antibodies.
. relapsed cervical cancer - ak-104 + chemo : orr=66-92%
. 1st line kidney cancer - medi5752 : orr=58%
it comes with a price: high immune related aes.
medi5752 is currently tested with chemo in 1st line nsclc. #asco22 | Medical Oncologist - Lung cancer & thymic tumors. Head of Clinical Research @GustaveRoussy - Head of Scientific Chairs Council @EORTC. Tweets are my own. | Individual | HCP |
reecur,paradigm,destiny-breast04 | ,panitumumab,trastuzumab deruxtecan | astrazeneca,amgen,takeda,daiichi sankyo | gi,other | 1 | ['mbc', 'destiny-04', 'sarcoma', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm', 'reecur'] | 6/5/2022 15:01 | 1,530,000,000,000,000,000 | #asco22 plenary session highlights paradigm: 1l mcrc left-side pani+mfolfox6 reecur: hd ifo better than tc in r ewing sarcoma destiny-04: t-dxd for hr+/- her2low mbc hormone resistant #oncology #mir #practicechanging | Medical Oncologist MD, BSc Vall d'Hebrón @vallhebron @VHIO
President Secció Metges MIR del COMB @COMBarcelona
Asesor en @SalutUIC
#oncology #research #MIR | Individual | HCP |
destiny-breast04,determination,reecur,paradigm | ,lenalidomide,panitumumab,dexamethasone,bortezomib,trastuzumab deruxtecan | astrazeneca,amgen,takeda,daiichi sankyo | gi,multiple myeloma,other | 1 | ['determination', 'sarcoma', 'crcsm', 'bcsm', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'mmsm', 'scmsm', 'breast', 'paradigm', 'destiny-breast04', 'reecur'] | 6/5/2022 18:00 | 1,530,000,000,000,000,000 | stay tuned for our update from #asco22.
our experts share their view on the impact of the lba plenary presentations: - - paradigm #crcsm - - reecur ewing sarcoma #scmsm
- - destiny-breast04 #bcsm
- prof lee - determination #mmsm #meded | COR2ED develops and implements high quality Independent Medical Education programmes to help improve the health of patients globally. #COR2ED #MedEd #IME | Company / Organization | Healthcare |
destiny-breast04,determination,reecur,paradigm | panitumumab,dexamethasone,bortezomib,bevacizumab,lenalidomide,trastuzumab deruxtecan | astrazeneca,amgen,takeda,daiichi sankyo,roche | gi,multiple myeloma,other | 1 | ['mbc', 'determination', 'sarcoma', '#gi', 'crcsm', 'bcsm', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'mmsm', 'breast', 'destinybreast04', 'paradigm', 'reecur', 'gism'] | 6/5/2022 15:29 | 1,530,000,000,000,000,000 | #asco22 #plenarysession summary 1. #destinybreast04: tdxd in low her2 mbc
2. #paradigm: pan + mfolfox6 vs bev + mfolfox6 in mcrc
3. #reecur: topotecan, cyclophos & hd ifos in ewing #sarcoma
4. #determination: rvd +/- asct + rev in myeloma
#bcsm #crcsm #gism #mmsm 1/5 | Practice changing #Oncology news from #CommunityOncologists perspective w/ Rohit Gosain @UPMCHillmanCC & Rahul Gosain @GuthrieClinic. Views are our own. | Company / Organization | Media / News |
destiny-breast04,paradigm | ,panitumumab,bevacizumab,trastuzumab deruxtecan | astrazeneca,amgen,takeda,daiichi sankyo,roche | gi,other | 1 | ['mbc', 'breast', 'destinybreast04', 'paradigm'] | 6/5/2022 15:53 | 1,530,000,000,000,000,000 | well done #myeloma rt : #asco22 #plenarysession summary 1. #destinybreast04: tdxd in low her2 mbc
2. #paradigm: pan + mfolfox6 vs bev + mf | Washington U. School of Medicine.
Assoc Director Hem/Onc Fellowship.
Myeloma, Amyloidosis, Leukemia, Lymphoma & BMT physician and researcher.
Tweets are my own. | Individual | HCP |
not tagged | not tagged | astrazeneca,arcellx,pmv pharmaceuticals,adicet bio,gilead sciences,affimed,merck,roche,beigene,abbvie,daiichi sankyo,elevation oncology,merus,gracell | not tagged | 1 | ['$pmvp', 'mrus', '$dsnky', '$azn', '$abbv', '$acet', '$bgne', '$mrus', '$elev', '$aclx', '$mrk', '$gild', '$rhhby', '$afmd'] | 6/6/2022 13:05 | 1,530,000,000,000,000,000 | $abbv $acet $afmd $aclx $azn $bgne $dsnky $elev $gild $grcl $mrk $mrus $pmvp $rhhby asco 2022 weekend story roundup | News and analysis of biomedical, biopharma, biotech, biosciences, pharmaceutical, and technology equities | Individual | Finance / Investment |
ev-301,COSMIC-021,chrysalis-2,tropics-02 | amivantamab-vmjw,sacituzumab govitecan,lazertinib,cabozantinib,osimertinib,atezolizumab,enfortumab vedotin | astrazeneca,astellas,genmab,gilead sciences,yuhan corp,exelixis,janssen,seagen,roche | gu,thoracic,other | 1 | ['chrysalis-2', 'ev-301', 'lcsm,(-blcsm)', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'bcsm', 'tropics-02', 'cosmic-021'] | 6/5/2022 13:27 | 1,530,000,000,000,000,000 | have you caught up with our #asco22 coverage for yet? head on over to the conference hub for reports on tropics-02, cosmic-021, ev-301, chrysalis & chrysalis-2, and more #bcsm #lcsm #guonc | medwireNews is an independent online medical news service. | Bot / Aggregator | Media / News |
Not Tagged | Not Tagged | astrazeneca,bayer | gu | 1 | ['inspire', 'bayerus', 'bayer'] | 6/5/2022 8:00 | 1,530,000,000,000,000,000 | this #cancersurvivorsday, we join and the entire cancer community to celebrate life and provide hope for those diagnosed with this disease. participate in our #asco22 photo mosaic to honor the cancer fighters in your life: #oncologyinspired | This is the official Twitter profile for Bayer in the U.S. Bayer is a Life Science company focused on health care and agriculture. | Company / Organization | Pharma / Biotech |
Not Tagged | Not Tagged | astrazeneca,bms | Not Tagged | 1 | ['thank you', 'bmsnews', 'bms', 'astrazeneca'] | 6/4/2022 9:35 | 1,530,000,000,000,000,000 | as #asco22 kicks off with an awesome opening session, we re sending out a special thank you to our opening session donors, (conqueror level) and ! | @ASCO's foundation funding research to conquer every cancer, for every patient, everywhere. | Company / Organization | Advocacy / Charity |
not tagged | not tagged | astrazeneca,bms | thoracic | 1 | ['lung', 'bms', 'bmsnews', 'bristol', 'astrazeneca'] | 6/7/2022 14:47 | 1,530,000,000,000,000,000 | . and bristol myers squibb are teaming up with association of community cancer centers to increase lung cancer screening in appalachia in a new initiative announced as part of the federal #cancermoonshot program. #asco2022 | PharmaVoice is the leading community for life sciences leaders to share their stories, voices and ideas. Subscribe at https://t.co/VQzsyqTs0b | Company / Organization | Healthcare |
not tagged | osimertinib,alisertib,sapanisertib | astrazeneca,calithera,takeda | not tagged | 1 | ['alisertib', 'osimertinib', 'sapanisertib'] | 6/6/2022 8:45 | 1,530,000,000,000,000,000 | poster at #asco22 looked at osimertinib plus either alisertib or sapanisertib in patients with resistance to osimertinib. low response rates, not moving forward. i like studies like this. helps us rapidly asses drugs. | Medical Oncologist at Memorial Sloan Kettering. Clinical focus on patients with lung & thymic cancers. COI: https://t.co/lXxGGb6HFw | Individual | HCP |
destiny-breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'destiny breast04', 'breast'] | 6/5/2022 8:23 | 1,530,000,000,000,000,000 | the 4 th from #asco22
destiny breast04
trastuzumab deruxtecan in previously treated her2-low advanced #breastcancer trastuzumab deruxtecan resulted in significantly longer pfs &os chemo os 23.9 mo 17.5 mo pfs 10.1 5.4 mo | Clinical Oncologist from Texas????Director of @OncoAlert ?? Proudly NIH, NCI & MDA trained. An ounce of prevention equals a pound of cure. Views are own?? | Individual | Media / News |
destiny-breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'breast', 'destiny-breast04'] | 6/5/2022 7:25 | 1,530,000,000,000,000,000 | destiny-breast04: in a phase 3 trial, trastuzumab deruxtecan resulted in longer progression-free and overall survival than the physician s choice of chemo among patients with her2-low breast cancer. #asco22 | The New England Journal of Medicine (https://t.co/YGfDrRsIhE) is the world’s leading medical journal and website. | Company / Organization | Publication / Journal |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'breast', 'destinybreast04'] | 6/5/2022 7:27 | 1,530,000,000,000,000,000 | a few hours before #asco22 plenary session, out in results of #destinybreast04 trial showing impressive survival improvement (doubling of pfs with hr 0.51 and major os gain) with #trastuzumabderuxtecan in #her2-low advanced #breastcancer | Associate Professor at @UniGenova & Medical Oncologist at @SanMartino_Ge. Prior @myESMO fellow. #BreastCancer #Fertility. Big fan of @sampdoria & @giroditalia. | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny-04', 'congrat', 'thank you'] | 6/5/2022 14:36 | 1,530,000,000,000,000,000 | standing ovation for #asco22 plenary session destiny-04 study. we did it. congrats to the entire team. thank you for all the patients who have participated. | MD Anderson Cancer Ctr, Breast Med Oncologist, Section Chief of Translational Breast Cancer Research, Executive Director of IBC Program | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destiny-breast04'] | 6/5/2022 14:33 | 1,530,000,000,000,000,000 | standing ovation after the #asco22 plenary presentation of destiny-breast04 by dr. shanu modi. a beautiful, powerful moment, that will remain in the history of breast oncology. | MD, Research Fellow @DanaFarber | @harvardmed | @IEOufficiale | @LaStatale. Interested in breast oncology, HER2, ADCs & good music. Coffee expert. | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destinybreast04'] | 6/5/2022 14:27 | 1,530,000,000,000,000,000 | finally it s time for the #destinybreast04 trial at #asco22 plenary session: so excited to be in the 2nd row of this big room to see such unprecedented results in the #breastcancer field...this will remain one of the most important moment in the history of this disease | Associate Professor at @UniGenova & Medical Oncologist at @SanMartino_Ge. Prior @myESMO fellow. #BreastCancer #Fertility. Big fan of @sampdoria & @giroditalia. | Individual | HCP |
destiny-breast04 | ,,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['mbc', 'breast', 'enhertu', 'destiny-breast04', '$azn'] | 6/5/2022 7:47 | 1,530,000,000,000,000,000 | #asco22 the most highly anticipated $azn/daiichi enhertu destiny-breast04 data are spectacular indeed! mpfs 9.9mo vs 5.1mo; hr=0.50; p<0.001 mos 23.4mo vs 16.8mo; hr=0.64; p=0.001 redefining rx for ~60% of her2- mbc by creating a new category: her2-low | #Biotech Investor | Recovering Scientist | May have L/S position in names mentioned | Opinions are strictly my own and not intended as investment advice | Individual | Research / Science |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destiny-breast04'] | 6/5/2022 14:33 | 1,530,000,000,000,000,000 | standing ovation for dr shanu modi after the destiny-breast04 amazing! | #BreastCancer Oncologist | #Immunotherapy @OSUCCC_James @PIIO_OSU | Assoc Ed @jitcancer | #BoyMom | #WomenInMedicine | #HoyaSaxa | #NIH alumnus | Tweets-My Own | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny-04', 'congrat', 'breast'] | 6/5/2022 14:32 | 1,530,000,000,000,000,000 | #asco2022 destiny-04. ild as expected. my thoughts: best in show for breast cancer this year. her2-low now on the table for adcs as a class. there is an accompanying nejm paper. the audience goes wild in a way i have not seen since the her2 2005 rock concert. congrats to dr modi. | Professor of Medicine, Stanford University; breast cancer doc | Individual | HCP |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/5/2022 7:03 | 1,530,000,000,000,000,000 | enhertu, a smart bomb drug, dramatically extends survival in breast cancer patients the most impactful data from #asco22 via | Reporter @statnews. I am the Night King of biotech. Data Are. Dog ??er. '21 Polk Award winner. Said one analyst: The likes of Adam Feuerstein attack viciously. | Individual | Media / News |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['bcsm', 'breast', 'destinybreast04'] | 6/5/2022 14:30 | 1,530,000,000,000,000,000 | db04 destinybreast04 shows improvement in pfs and os in her2 low breast cancer, fundamentally changing the way we define the disease. #asco22 #bcsm | Director Breast Oncology, Lifespan Cancer Institute, Legorreta Cancer Center Brown Univ | Medical Advisor @drloveresearch | #bcsm #clinicaltrials | Views Mine | Individual | HCP |
destiny-breast04 | ,,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', 'destiny-breast04', '$azn', '$dsnky'] | 6/5/2022 7:00 | 1,530,000,000,000,000,000 | has enhertu just redefined her2 negative breast cancer? pfs doubles to 10.1 months over chemo for a 49% risk reduction and os hits 23.9 months (hr 0.64) in her2 low population. my first take on the destiny-breast04 trial at #asco22: $azn $dsnky | Pharma and biotech reporter, found a home at Evaluate Vantage. | Individual | Media / News |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['bcsm', 'breast', 'destiny-breast04'] | 6/5/2022 14:35 | 1,530,000,000,000,000,000 | a packed house and a standing ovation for dr shanu modi s practice changing results from the destiny-breast04, a randomized, phase 3 study. #acso22 #bcsm | The official account of Memorial Sloan Kettering Cancer Center, the Sloan Kettering Institute, and Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences | Company / Organization | Hospital / Clinic |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | Not Tagged | 1 | ['enhertu'] | 6/5/2022 7:26 | 1,530,000,000,000,000,000 | if you're a tumor with any her2, enhertu hurts you. #linestoocheesytouse #asco22 via | Writing and events at STAT. This is biology's century; Every data point has a face. Part of team that won ‘21 Polk Award. | Individual | Research / Science |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny04'] | 6/6/2022 9:14 | 1,530,000,000,000,000,000 | it's not just the drugs that are promising. the minds are, too! dr. lorusso's discussion of destiny04 included recent work by , & , 3 rising stars in oncology! the future is bright! #asco22 | She/Her. Living w #MetastaticBC since '13 & advocating for people w MBC to LIVE. #AntiRacist #InclusionPledge #bcsm @GRASPtweets @OncoAlert ???? ???? ???? | Individual | Advocacy / Charity |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'breast', 'destiny-breast04'] | 6/5/2022 14:28 | 1,530,000,000,000,000,000 | destiny-breast04: trastuzumab deruxtecan (t-dxd) in patients with her2-low advanced breast cancer: better pfs and os with t-dxd regardless of hormone receptor status! orr 50%, cbr 70% #asco22 | Pursuing to improve cancer prevention and care. Medical Oncologist @AnkaraUni | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['bcsm', 'breast', 'destinybreast04'] | 6/5/2022 14:29 | 1,530,000,000,000,000,000 | #asco22 #plenary3 dr. modi presents "t-dxd vs physician s choice in her2-low unresectable and/or metastatic #bcsm: #destinybreast04 mpfs: 10.1 v 5.4 m, all: 9.9 vs 5.1 mos (hr+): 23.9 vs 17.5 m, all: 23.4 vs 16.8 mpfs/os, rx duration but 12% ild | Fellow @MayoHemeOnc | @UConnIM| @UTexasSPH| @MDAndersonNews|@COVID19nCCC| #SoMeEditor @JCOCCI_ASCO| Co-Host @HemOncFellows https://t.co/dsiuV460lQ, Views my own | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny breast04', 'breast'] | 6/5/2022 14:37 | 1,530,000,000,000,000,000 | amazing to witness standing ovation at #asco22 for the results of destiny breast04 which completely redefine how we think about her2 analyses in clinical practice. bravo! | Breast Medical Oncologist - @MayoClinic. Focus on #TNBC and #immunoonc. Opinions are mine, not my employer’s. Orgullosamente ecuatoriano ???? | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | gi,other | 1 | ['trastuzumab', 'mbc', 'breast', 'destinybreast04', 'paradigm'] | 6/5/2022 16:22 | 1,530,000,000,000,000,000 | #asco22
#destinybreast04 practice-changing results for #trastuzumabderuxtecan in patients with #her2low #mbc after 1-2 prior chemotherapy lines paradigm shift for the classification and treatment of metastatic #breastcancer #shanimodi | @EORTC Breast Cancer Group’s (BCG) mission is to develop new standards of care for #BreastCancer patients through innovation and multidisciplinary research. | Company / Organization | Healthcare |
Not Tagged | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/5/2022 7:14 | 1,530,000,000,000,000,000 | enhertu, a smart bomb drug, dramatically extends survival in breast cancer patients probably the biggest #asco22 news. | Writing and events at STAT. This is biology's century; Every data point has a face. Part of team that won ‘21 Polk Award. | Individual | Research / Science |
DESTINY-Breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'breast'] | 6/5/2022 13:22 | 1,530,000,000,000,000,000 | thrilled to have participated in this practice changing trial! #asco22 and now: trastuzumab deruxtecan in previously treated her2-low advanced breast cancer | nejm | null | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destiny-breast04'] | 6/5/2022 14:17 | 1,530,000,000,000,000,000 | her2 targeted therapy has not been successful in treating cancer that is her2-low, until now. msk s dr. modi shares the encouraging results from the destiny-breast04, a randomized, phase 3 study at #asco22. | The official account of Memorial Sloan Kettering Cancer Center, the Sloan Kettering Institute, and Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences | Company / Organization | Hospital / Clinic |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destiny-breast04'] | 6/5/2022 14:32 | 1,530,000,000,000,000,000 | if there was an applause meter at plenary session destiny-breast04 just won #asco22 with a standing ovation! | Director, GI Oncology, @Intermountain. Interests: neuroendocrine tumors, cancer syndromes, empathy (even had a Whipple myself). Tweets my own. | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['bcsm', 'breast', 'destiny-breast04'] | 6/5/2022 16:00 | 1,530,000,000,000,000,000 | asco expert shares how the destiny-breast04 trial will redefine how #breastcancer is classified and expand the population of pts who can benefit from her2-targeted therapy #asco22 #bcsm | Account of the American Society of Clinical Oncology & its affiliate the Association for Clinical Oncology. Assoc tweets labeled #ASCOAdvocacy. RTs ? endorse. | Company / Organization | Professional |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destinybreast04', 'destiny,breast,4', 'breast'] | 6/6/2022 5:57 | 1,530,000,000,000,000,000 | the #oncoalerttoptweet day 3 #asco22 tweet the very well deserved standing ovation for #destinybreast04 at the asco22 plenary best, | ?? Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees ?? We are #OncoAlert ?? | Bot / Aggregator | Media / News |
destiny-breast04 | ,,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['mbc', 'destiny breast04', 'breast', 'enhertu'] | 6/5/2022 7:12 | 1,530,000,000,000,000,000 | impressive data for enhertu in destiny breast04 study. 6m os gain in er+ her2 1+/2+
10m os gain in er- her2 1+/2+.
the bar is raised in mbc! | Breast cancer specialist and professor @DanaFarber Cancer Institute and @HarvardMed. Tweets are my own and not medical advice. COI disclosure: no COI. | Individual | HCP |
DESTINY-Breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu', 'daiichisankyous', 'fierce', 'astrazeneca'] | 6/5/2022 7:04 | 1,530,000,000,000,000,000 | with phenomenally spectacular data at #asco22, and 's enhertu could transform how breast cancer is treated by opening a new category: her2-low. | Tweets from the Fierce Life Sciences editorial team | Company / Organization | Media / News |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['bcsm', 'breast', 'destiny-breast04'] | 6/5/2022 14:29 | 1,530,000,000,000,000,000 | what better way to celebrate #nationalcancersurvivorsday ! #asco22 #destiny-breast04 #bcsm | Medical Director Clinical Operations, Cancer Survivorship Program; Breast Oncologist @SylvesterCancer, AD of Community Outreach. #WomenInMedicine tweets=my own | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['bcsm', 'breast', 'destiny-breast04'] | 6/5/2022 14:33 | 1,530,000,000,000,000,000 | standing ovation for results of destiny-breast04. this will change practice for 50% of patients with metastatic breast cancer. this is why we all went into this field. #bcsm #asco22 | Breast & gyn med onc @valleyhospital in NJ. Focus on survivorship and ?????? onc. All opinions my own. Retweets not endorsements. Host of INTERLUDE podcast ?? | Individual | HCP |
DESTINY-Breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'congrat', 'breast'] | 6/5/2022 8:15 | 1,530,000,000,000,000,000 | in concurrent with #asco22 plenary:
trastuzumab deruxtecan in previously treated her2-low advanced breast cancer finally a meaningful therapy for her-2 low #breastcancer congratulations and colleagues. | Pancreatic cancer researcher and GI pathologist. Striving to improve the lives of patients with cancer. | Individual | HCP |
DESTINY-Breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'breast'] | 6/5/2022 8:33 | 1,530,000,000,000,000,000 | meaningful improvements in both progression free survival and overall survival but with notable rates of ild.
#asco22 #dbo4 trastuzumab deruxtecan in previously treated her2-low advanced breast cancer | nejm | Director Breast Oncology, Lifespan Cancer Institute, Legorreta Cancer Center Brown Univ | Medical Advisor @drloveresearch | #bcsm #clinicaltrials | Views Mine | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny-04', 'bcsm'] | 6/5/2022 14:33 | 1,530,000,000,000,000,000 | standing ovation after destiny-04 trial results presentation at plenary session #asco22 #bcsm | Medical Oncology Fellow @NIO_PIB,
Visiting investigator @MSKCancerCenter,
YOC Member @myESMO
#Sarcoma #melanoma
He/him ?????????? | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['congrat', 'breast', 'destinybreast04'] | 6/5/2022 14:52 | 1,530,000,000,000,000,000 | dear great choice inviting dr. lorusso to do this discussion. her multi-disease, drug development lens was refreshing and wonderful! dear pass on my warm congratulations since i can t congratulate her here on twitter. #asco22 #destinybreast04 | Director Breast Oncology, Lifespan Cancer Institute, Legorreta Cancer Center Brown Univ | Medical Advisor @drloveresearch | #bcsm #clinicaltrials | Views Mine | Individual | HCP |
DESTINY-Breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'bcsm', 'breast'] | 6/5/2022 8:13 | 1,530,000,000,000,000,000 | today #asco22 is excited about trastuzumab deruxtecan but i have dr andre iibawi s words from yesterday in my ears - nearly 25 years after fda approval of trastuzumab it is *still* only available to a third of global breast cancer patients
#bcsm | #NHS Oncologist, @UHSussex Macmillan National Clinical Adviser, #radonc #BHAFC #gerionc (He/Him) #Brighton pic by @FinnHop | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['mbc', 'breast', 'destiny-breast04'] | 6/5/2022 14:18 | 1,530,000,000,000,000,000 | plenary abstract 3: dr. modi: destiny-breast04, t-dxd vs chemo in her2 low mbc. dropping the summary slide first, and commenting on how this affects 50% of patients with her2+ mbc. #asco22 | Gastrointestinal medical oncology, cancer of unknown primary, and value-based cancer care delivery. Tweets mine. | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny 04', 'bcsm'] | 6/5/2022 14:20 | 1,530,000,000,000,000,000 | dr. shanu modi - starting with a summary of the most anticipated and exciting results of destiny 04 - t-dxd versus tdm1 #asco22 #cancer #bcsm | Prof. & Chair Dept. of Heme and Oncology @ClevelandClinic @NRGonc Deputy Editor @JCOOP_ASCO Tweets are mine. No act of #Kindness is ever wasted #CleClinicCancer | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny-04'] | 6/5/2022 14:28 | 1,530,000,000,000,000,000 | #asco2022 destiny-04, modi, cont. pfs stat sig with 10.1 vs 5.4 mo with hr 0.51 for hr positive and similar for all pts. os hr 0.64, 17.5 to 23.9 mo. for hr pos with similar all patients results. forrest plot shows no differences. safety profile similar to prior t-dxd trials. | Professor of Medicine, Stanford University; breast cancer doc | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny breast04', 'breast'] | 6/5/2022 15:14 | 1,530,000,000,000,000,000 | amid the adulation over destiny breast04, were and i the only people to notice the difference between the #asco22 abstract and the nejm paper? | Journalist at Evaluate Vantage. Proudly blocked by @JohnCendpts. Interested in: oncology, immunology. Not interested in: what stock you bought today. | Individual | Finance / Investment |
HERB | trastuzumab | astrazeneca,daiichi sankyo | not tagged | 1 | ['trastuzumab'] | 6/6/2022 6:57 | 1,530,000,000,000,000,000 | the #oncoalerttoptweet day 3 #asco22 tweet #precisionmedicine happening at #asco22 -targeting her2 positive biliary tract #cancer using trastuzumab-deructecan 300+ pts screened orr 30% in her2+pts interesting pfs/os signal best | ?? Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees ?? We are #OncoAlert ?? | Bot / Aggregator | Media / News |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'destiny breast04', 'breast'] | 6/5/2022 8:24 | 1,530,000,000,000,000,000 | yet another one at #asco22 destiny breast04 trastuzumab deruxtecan resulted in significantly longer pfs &os chemo | ?? Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees ?? We are #OncoAlert ?? | Bot / Aggregator | Media / News |
DESTINY-Breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'mbc', 'bcsm'] | 6/5/2022 11:55 | 1,530,000,000,000,000,000 | trastuzumab deruxtecan is new standard of care for her2-low mbc #asco22 #bcsm #oncology | Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management. | Company / Organization | Publication / Journal |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'breast', 'destiny-breast04'] | 6/5/2022 14:28 | 1,530,000,000,000,000,000 | trastuzumab deruxtecan versus tpc in her2-low unresectable and/or metastatic #breastcancer destiny-breast04 study. this is the future, now. #asco22 #oncoalerttoptweet #oncoalert | Associate Professor, Florence University, Italy. Clinical Oncologist with focus on breast, radiation, research. Opinions are my own. RT not endorsement. | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['tnbc', 'mbc', 'destiny breast04', 'breast', 'friends'] | 6/5/2022 14:33 | 1,530,000,000,000,000,000 | destiny breast04, great results, practice changing for her2low and mtnbc. watching with my mbc friends, all of us with tears in our eyes. met in the moment by a standing ovation #asco22 | Scientist and Advocate - Angiosarcoma survivor making hay while the sun still shines. Ally. she/her | Individual | Research / Science |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'bcsm', 'breast', 'destiny-breast04'] | 6/5/2022 14:43 | 1,530,000,000,000,000,000 | encouraging results from destiny-breast04 presented by dr. shanu modi demonstrating improved overall survival (23.4 vs 16.8 mos) in her2-low #breastcancer using trastuzumab-deruxtecan (t-dxd) rather than physician's treatment choice. #asco22 #bcsm | Mother of Warlords & Slayer of Cancers|Brst/Gyn #radonc @WeillCornell @nyphospital @nypbrooklyn | #globaloncology | #globalhealth|#MedEd|#gyncsm|#bcsm???????? | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destinybreast04'] | 6/5/2022 14:47 | 1,530,000,000,000,000,000 | results of #destinybreast04: a new era in #breastcancer treatment. dr modi received a standing ovation. exciting moment. i hope more patients will benefit from this treatment. #asco22 | Interested in #Breastcancer #Cancerreseach. | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'breast', 'destiny-breast04'] | 6/5/2022 15:02 | 1,530,000,000,000,000,000 | destiny-breast04: trastuzumab deruxtecan (t-dxd) in patients with her2-low advanced breast our destiny is not written for us, but by us -barack obama #asco22 #oncology #breastcancer | Mexican ???? / Internal Medicine????/ Oncology Fellow ????@incmnszmx / Dog lover ???? / Sui géneris | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destiny-breast04'] | 6/5/2022 15:22 | 1,530,000,000,000,000,000 | summing up #asco22 in 1 word! destiny-breast04 | GU oncologist, clinical trialist, Director GU Oncology @CleclinicMD Tweets my own, RT/Likes not active endorsement. | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['tnbc', 'bcsm', 'breast', 'destiny-breast04'] | 6/5/2022 15:33 | 1,530,000,000,000,000,000 | thoughts on destiny-breast04. thread. we need to diversify clinical trials! 53 of 484 (11%) classified as "other". an audience & dr. modi touched on this issue. tnbc among black women & they need to be seen in these studies. #asco22 #bcsm #healthequity | Mother of Warlords & Slayer of Cancers|Brst/Gyn #radonc @WeillCornell @nyphospital @nypbrooklyn | #globaloncology | #globalhealth|#MedEd|#gyncsm|#bcsm???????? | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destinybreast04', 'destiny,breast,4', 'breast', 'trastuzumab'] | 6/6/2022 5:56 | 1,530,000,000,000,000,000 | the #oncoalerttoptweet day 3 #asco22 #destinybreast04 trastuzumab deruxtecan resulted in significantly longer pfs &os chemo os 23.9 mo 17.5 mo pfs 10.1 5.4 mo tweet | ?? Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees ?? We are #OncoAlert ?? | Bot / Aggregator | Media / News |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destinybreast04', 'destiny,breast,4', 'breast'] | 6/6/2022 6:29 | 1,530,000,000,000,000,000 | the #oncoalerttoptweet day 3 #asco22 tweet about that standing ovation for
#destinybreast04 a game changer best, | ?? Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees ?? We are #OncoAlert ?? | Bot / Aggregator | Media / News |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny-breast04', 'breast', 'daiichisankyous'] | 6/4/2022 11:00 | 1,530,000,000,000,000,000 | looking forward to having our destiny-breast04 data in #her2 low metastatic #breastcancer featured during tomorrow s plenary session at #asco22. | Daiichi Sankyo US’s channel featuring our biopharmaceutical news, passion for innovation & compassion for patients. See our guidelines: https://t.co/4iEAbpw1Wx | Company / Organization | Pharma / Biotech |
DESTINY-Breast03 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'breast'] | 6/4/2022 14:55 | 1,530,000,000,000,000,000 | catch our amazing faculty from presenting: trastuzumab deruxtecan trastuzumab emtansine in her2 unresectable and/or metastatic #breastcancer safety follow up direct from #asco22 | Clinical Oncologist from Texas????Director of @OncoAlert ?? Proudly NIH, NCI & MDA trained. An ounce of prevention equals a pound of cure. Views are own?? | Individual | Media / News |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny-04', 'love this'] | 6/5/2022 14:26 | 1,530,000,000,000,000,000 | just wow. i love this drug. destiny does it again. results from destiny-04, 6mo improvements in pfs and os. #asco22 | Breast medical oncologist at Levine Cancer Institute @LevineCancer @LCI_YWBP | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['bcsm', 'breast', 'destiny-breast04'] | 6/5/2022 14:29 | 1,530,000,000,000,000,000 | destiny-breast04 results are practice changing with #tdxd showing benefit in low her2 expressing tumors irrespective of er status. potential improvement in pfs and os for ~50% of pretreated breast patients #bcsm #asco22 | #BreastCancer Oncologist | #Immunotherapy @OSUCCC_James @PIIO_OSU | Assoc Ed @jitcancer | #BoyMom | #WomenInMedicine | #HoyaSaxa | #NIH alumnus | Tweets-My Own | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'enhertu'] | 6/5/2022 14:30 | 1,530,000,000,000,000,000 | a new standard for her-2 low ( hormone receptor + and triple negative) advanced #breastcancer #asco22 t-dxd - enhertu | Prof. & Chair Dept. of Heme and Oncology @ClevelandClinic @NRGonc Deputy Editor @JCOOP_ASCO Tweets are mine. No act of #Kindness is ever wasted #CleClinicCancer | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['mbc', 'lba3 '] | 6/5/2022 14:30 | 1,530,000,000,000,000,000 | dr. modi lba3 #asco22: bottom line, benefits of t-dxd seen in all subgroups of her2 mbc, and the os advantage should make this practice-changing per dr. modi | Oncologist & Chief Medical Science Officer @ASCO #CancerLinQ. Classical/choral music fan ???? https://t.co/GxpBhxmsFj. RT or like may mean I agree; or not. Tweets=only moi | Individual | Professional |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['breast', 'destiny-breast04'] | 6/5/2022 14:31 | 1,530,000,000,000,000,000 | live look at her2 ihc results after destiny-breast04 #asco22 | Director, GI Oncology, @Intermountain. Interests: neuroendocrine tumors, cancer syndromes, empathy (even had a Whipple myself). Tweets my own. | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['mbc', 'destiny04', 'breast'] | 6/5/2022 14:33 | 1,530,000,000,000,000,000 | standing ovation @ plenary session on the much awaited #destiny04 by dr. modi - t-dxd establishes new standard of care in her-2 low metastatic breast cancer both hr(+)and (-) #asco22 #mbc also published in today | GU Oncology Fellow | NOLA Heme/Onc Alumni | Interested in GU, Immuno Onc & Med Ed | #ASCO22 Featured Voice | COI: https://t.co/X1Y9QuHs6L | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | gi,other | 1 | ['mbc', 'improve ', 'breast', 'destiny-breast04'] | 6/5/2022 14:47 | 1,530,000,000,000,000,000 | destiny-breast04: standing ovation more than deserved . t-dxd showed to improve pfs and os in pretreated her2-low (1+ and 2+ ish -) #mbc patients vs tpc. "the adc era has just begun also in her2-low bc". these results speak for themselves. #asco22 #bcareporter | null | Company / Organization | Healthcare |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['bcsm', 'breast', 'destiny-breast04'] | 6/5/2022 14:50 | 1,530,000,000,000,000,000 | patricia lorusso of discusses destiny-breast04: challenges of assessing her2 status; t-dxd activity in her2-mutated cancers; mechanism of resistance. new standard of care for her2-low breast cancer. we need improved assays to identify who will benefit. #bcsm #asco22 | Medical oncologist @Intermountain, Director of Breast Oncology. Clinical research, quality improvement, cardio-oncology, provider wellness. All tweets my own. | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['congrat', 'breast', 'destiny-breast04'] | 6/5/2022 15:00 | 1,530,000,000,000,000,000 | phase iii study "destiny-breast04" show a statistically significant and clinically meaningful benefit in pfs and os compared to standard-of-care treatment. congratulations on your excellent presentation in #asco22 | Soy Internista y Oncólogo en la ciudad de Puebla. El tratamiento del cáncer debe de ser personalizado y adaptarse a las necesidades individuales del paciente. | Individual | HCP |
DESTINY-Breast04 | trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['trastuzumab', 'bcsm', 'breast'] | 6/5/2022 17:10 | 1,530,000,000,000,000,000 | #asco22 plenary session fam-trastuzumab deruxtecan-nxki doubles progression-free survival in her2-low metastatic breast cancer - the asco post #bcsm | Associate Director Community Outreach- Thoracic Oncology-University of Miami @SylvesterCancer , Boricua en la Luna, Tweets are my own. (she/her) | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destinybreast04', 'destiny,breast,4', 'db04', 'breast'] | 6/6/2022 6:01 | 1,530,000,000,000,000,000 | the #oncoalerttoptweet day 3 #asco22 tweet db04 #destinybreast04 shows improvement in pfs and os in her2 low #breastcancer fundamentally changing the way we define the disease best, | ?? Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees ?? We are #OncoAlert ?? | Bot / Aggregator | Media / News |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['destiny,breast,4', 'breast', 'trastuzumab', 'destiny-breast04'] | 6/6/2022 10:03 | 1,530,000,000,000,000,000 | extraordinary scenes at the #asco22 plenary session as destiny-breast04 establishes t-dxd as the new standard of care in her2-low hr+/hr- metastatic #breastcancer standing ovation from attendees and excitement not seen since the launch of adjuvant trastuzumab | Radiation Oncologist and Clinical Director, wouldbe cyclist, sometimes pianist. Views are my own, RTs not | Individual | HCP |
destiny-breast04 | ,trastuzumab deruxtecan | astrazeneca,daiichi sankyo | other | 1 | ['bcsm', 'db04', 'mbc'] | 6/6/2022 15:58 | 1,530,000,000,000,000,000 | most anticipated: db04 :
- t-dxd significantly os, pfs and orr in her2 low mbc regardless of hr status. - os of ~ 10m in hr-ve mbc and ~ 6m for hr+ve - ild with t-dxd 12% of cases, 3 g5. new soc more hope for our patients. #asco2022 #asco22 #bcsm #db04 | ???????? ?? ??????? - ?????? ???????? Medical Oncologist #breastcancer. MD Anderson Alumni “All tweets are my own and RT?endorsement” | Individual | HCP |